Mundipharma
CAMBRIDGE, England, October 10, 2011 -
Experts call for patients to talk to their doctor to proactively assess their pain
New research released today to mark European Week Against Pain reveals that, in more than half of cases, peoples' levels of pain across Europe are not being adequately assessed.
HAMBURG, Germany, September 22, 2011 -
A group of European pain specialists today launches a White Paper highlighting the widespread inadequate management of chronic pain and calls for governments to prioritise its prevention and management[1].
CAMBRIDGE, England, December 6, 2010 - Data presented today at the World Allergy
Organization (WAO) International Conference have shown that: clinical
efficacy, safety, tolerability and speed of onset of a long-acting
Beta2-agonist (LABA), potency of an inhaled corticosteroid (ICS), and
flexibility of dosing are the most important attributes that influence an
expert's choice of a combination therapy to treat asthma.[1] This study,
undertaken under the auspices of the Global Allergy and Asthma European
Network (GA2LEN), used the Delphi process, a validated consensus-development
methodology that enables a group of experts to deal with a complex problem
through rounds of structured feedback.
New Combination for Asthma Shows Encouraging Results in Delivering Efficacy and Fast Onset of Action
CAMBRIDGE, England, September 19, 2010 - Data presented at the European Respiratory Society (ERS) congress
demonstrate that a new fixed-dose combination therapy of fluticasone
propionate (FP), an inhaled corticosteroid, and formoterol fumarate (FORM), a
long-acting beta2-agonist, is as effective in treating asthma as one of the
current market leaders in Europe, fluticasone propionate/salmeterol xinafoate
(FP/SAL), but has a more rapid onset of action(1).
CAMBRIDGE, England, June 18, 2010 - Mundipharma announced today that 13 European countries to date have
received approval of Lodotra(R) (modified-release prednisone), a new
treatment for rheumatoid arthritis (RA) which offers the benefits of
conventional prednisone, with the added advantage of a clinical reduction in
morning stiffness, a barrier to the morning functioning of people with RA.
